Title : In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

Pub. Date : 2005 Jun 1

PMID : 15930265






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Two such Bcr-Abl inhibitors are currently being evaluated in clinical trials: the improved potency, selective Abl inhibitor AMN107 and the highly potent dual Src/Abl inhibitor BMS-354825. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 Two such Bcr-Abl inhibitors are currently being evaluated in clinical trials: the improved potency, selective Abl inhibitor AMN107 and the highly potent dual Src/Abl inhibitor BMS-354825. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens